A Study Comparing Short-course Antifungal Therapy (SCAT) 7 Day vs Standard 14 Day Antifungal Therapy for Uncomplicated Candidemia

Short-Course Antifungal Therapy vs Standard of Care (14 Day Therapy) for Uncomplicated Candidemia (SCAT)

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06907992

Acronym

SCAT

Enrollment

150

Registered

2025-04-03

Start date

2025-05-01

Completion date

2027-12-31

Last updated

2025-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Candidemia

Keywords

candidemia, uncomplicated candidemia, antifungal therapy, echinocandin, caspofungin, micafungin, rezafungin, anidulafungin

Brief summary

The goal of this clinical trial is to assess whether a seven-day course of standard of care (echinocandin) antifungal therapy is non-inferior to a 14-day course of echinocandin antifungal therapy in patients with uncomplicated candidemia in terms of clinical, mycologic, adverse events and all cause mortality.

Interventions

DRUGAntifungal treatment

Short-course antifungal therapy (7 days) versus standard of care antifungal therapy (14 days)

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Patients ≥ 18 years of age 2. Uncomplicated candidemia (positive blood culture only). No evidence of invasive candidiasis at day 1 or until day 7. 3. Received \< 5 days of prior antifungal therapy 4. Informed Consent for randomization 5. Patients that did not consent to randomization have consented to be used as a natural history (controls) and will allow collection of available data from the medical record.

Exclusion criteria

1. Inadequate source control (e.g., unable to remove endovascular devices, urinary catheters). 2. Invasive candidiasis of any type (e.g., deep seated candidiasis from sources other than blood) 3. Abnormal LFTs \> 10-fold 4. Greater than 5 days of prior antifungal therapy 5. Endovascular devices that cannot be removed. 6. Immunocompromised patients (AIDS/HIV; solid organ transplant, bone marrow transplant patients, oncology patients receiving chemotherapy, neutropenic patients (ANC of \< 1,500 cells/L 7. Neutropenic at time of consent (what does this mean) 8. Break-through candidemia (people with prior candidemia who relapsed) after treatment with antifungal therapy) 9. Unable to provide informed consent from either the patient or legally authorized authority (LAR) 10. Expected mortality within 96 hours

Design outcomes

Primary

Measure	Time frame	Description
Eradication of candida from the blood at day 7 or day 14	14 Days	Blood culture monitoring at day 7 and day 14

Countries

United States

Contacts

Primary ContactAprile Osborn, MSN

aosborn@augusta.edu706-721-0309

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026